A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, dose-escalation study designed to determine the maximum
tolerated dose (MTD) by evaluating dose-limiting toxicities (DLTs) and to evaluate the
safety, tolerability, pharmacokinetics, anti-tumor effect, and biomarkers of ERY974 in
combination with atezolizumab and bevacizumab following premedication with tocilizumab in
patients with locally advanced or metastatic HCC.